<DOC>
	<DOCNO>NCT01301495</DOCNO>
	<brief_summary>In study , newly design FDA approve fully cover metal stent use palliate 20 patient malignant lesion esophagus . Dysphagia score assess treatment confirm efficacy</brief_summary>
	<brief_title>Prospective Evaluation New Covered Metal Stent Malignant Lesions Esophagus</brief_title>
	<detailed_description>The incidence esophageal cancer increase , despite advance treatment , prognosis still poor [ 1-4 ] . At presentation , 50-60 % patient unresectable disease [ 5,6 ] . For patient , palliation goal particular focus relief dysphagia , major etiology morbidity [ 5,6 ] . Presently , Self expand metal stent ( SEMS ) become treatment choice dysphagia associate unresectable esophageal GE junction malignancy . In study , newly design FDA approve fully cover metal stent use palliate 20 patient malignant lesion esophagus . Dysphagia score assess treatment confirm efficacy The objective : 1 . To evaluate newly fully cover metal stent , HANAROSTENT provide adequate palliation cancerous lesion esophagus ; 2 . To determine whether non-inferior efficacy safety esophageal stent currently available UVa minimal complication improvement symptom</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Inoperable malignant obstruction esophageal gastric cardia Malignant fistula esophagus ans respiratory tree Recurrent cancer prior radiation Patient unstable endoscopic procedure Previous esophageal stenting Tumor growth within 2 cm upper esophageal sphincter Pregnant woman ( self report , pregnancy test do per protocol )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Esophageal Cancer , Malignant , Dysphagia , Esophagus , Cancer</keyword>
</DOC>